EUVIMEDEUVIMED entdecken
Multizentrische StudieFall-Kontroll-Studie

Comparative Outcomes of Candida auris Bloodstream Infections: A Multicenter Retrospective Case-Control Study

Samuel P Simon, Rosanna Li, Michael Silver, Justin Andrade, Biju Tharian, Lung Fu, Diana Villanueva, Daniel Gonzalez Abascal, Ariel Mayer, James Truong, Nilka Figueroa, Monica Ghitan und 2 weitere

Clinical Infectious Diseases · 08.02.2023 · 76 (3) · e1436-e1443

DOI: 10.1093/cid/ciac735 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 05.09.2022. Verfasst von Samuel P Simon und 13 weiteren Autor:innen. Beteiligte Einrichtung: Maimonides Medical Center, Brooklyn, New York, USA. Hauptthemen laut MEDLINE: Candidemia. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study was performed to compare clinical characteristics and outcomes between patients with bloodstream infections (BSIs) caused by Candida auris and those with BSIs caused by other Candida spp.

Methods

A multicenter retrospective case-control study was performed at 3 hospitals in Brooklyn, New York, between 2016 and 2020. The analysis included patients ≥18 years of age who had a positive blood culture for any Candida spp. and were treated empirically with an echinocandin. The primary outcome was the 30-day mortality rate. Secondary outcomes were 14-day clinical failure, 90-day mortality rate, 60-day microbiologic recurrence, and in-hospital mortality rate.

Results

A total of 196 patients were included in the final analysis, including 83 patients with candidemia caused by C. auris. After inverse propensity adjustment, C. auris BSI was not associated with increased 30-day (adjusted odds ratio, 1.014 [95% confidence interval, .563–1.828]); P = .96) or 90-day (0.863 [.478–1.558]; P = .62) mortality rates. A higher risk for microbiologic recurrence within 60 days of completion of antifungal therapy was observed in patients with C. auris candidemia (adjusted odds ratio, 4.461 [95% confidence interval, 1.033–19.263]; P = .045).

Conclusions

C. auris BSIs are not associated with a higher mortality risk than BSIs caused by other Candida spp. The rate of microbiologic recurrence was higher in the C. auris group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CandidemiaHumansAntifungal AgentsCandida aurisRetrospective StudiesCase-Control StudiesCandidaMicrobial Sensitivity Tests

Stichwörter der Autor:innen

Candida auriscandidemiaechinocandinmicafungin

Substanzen

Antifungal Agents

Autor:innen und Institutionen

  • Maimonides Medical Center, Brooklyn, New York, USA.
  • The Brooklyn Hospital Center, Brooklyn, New York, USA.
  • Coney Island Hospital, Brooklyn, New York, USA.

Zitieren

APA

Simon, S. P., Li, R., Silver, M., Andrade, J., Tharian, B., Fu, L., Villanueva, D., Abascal, D. G., Mayer, A., Truong, J., Figueroa, N., Ghitan, M., Chapnick, E., & Lin, Y. S. (2023). Comparative Outcomes of Candida auris Bloodstream Infections: A Multicenter Retrospective Case-Control Study. Clinical Infectious Diseases, 76(3), e1436-e1443. https://doi.org/10.1093/cid/ciac735

Vancouver

Simon SP, Li R, Silver M, Andrade J, Tharian B, Fu L, et al. Comparative Outcomes of Candida auris Bloodstream Infections: A Multicenter Retrospective Case-Control Study. Clinical Infectious Diseases. 2023;76(3):e1436-e1443. doi:10.1093/cid/ciac735

BibTeX
@article{Simon2023,
  author = {Simon, Samuel P and Li, Rosanna and Silver, Michael and Andrade, Justin and Tharian, Biju and Fu, Lung and Villanueva, Diana and Abascal, Daniel Gonzalez and Mayer, Ariel and Truong, James and Figueroa, Nilka and Ghitan, Monica and Chapnick, Edward and Lin, Yu Shia},
  title = {Comparative Outcomes of Candida auris Bloodstream Infections: A Multicenter Retrospective Case-Control Study},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {76},
  number = {3},
  pages = {e1436--e1443},
  doi = {10.1093/cid/ciac735}
}
Kostenlos starten →